Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies

In separate trials, Takeda’s Nesina and BMS/AstraZeneca’s Onglyza demonstrated neither cardiovascular benefit nor harm in type 2 diabetics at increased risk for such events. The DPP-4 inhibitors also were not associated with increased rates of pancreatitis, which has been a safety concern for the class.